Is Indian Life Sciences Really in Limelight?

1
Is Indian Life Sciences Really in Limelight?
2

• Indiathe land encompassing prodigious flora and
  fauna is flourishing with untapped opportunity in
  the field of life sciences. The rapidly
  increasing demands in health care, food,
  medicines, all such urgent attention-screaming
  issues could be reclaimed through development in
  the biotech sector of this country.

3

• Currently, stats show that there are about 8.1
  companies in pharmaceutical sector, 19.3 in RD
  services and 2.3 in therapeutics and diagnostics
  services in India.  Here are few signs debating
  on- is India really doing justly in the field of
  life sciences?

4
Aid from Homeland

• Better late than never! Government of India
  proves to be a tower of strength in nurturing
  this sector. In Union budget of 2015-2016,
  US1.09 billion ( ?7288 crore approx.) has been
  allotted for the field of biotech research.

5

• It is being estimated that if US4.01 -5.02
  billion is being invested annually for the next
  five years, biotech sector can grow at an average
  rate of about 30 contributing to about US100
  billion by 2025.

6

• The Department of Biotechnology, Ministry of
  Science Technology, is actively recognizing
  the needs in this sector and is acting as a
  pillar of support  for vehement scientists and
  start-ups by providing various grants and funds
  thereby motivating them in spiraling up and
  investing in innovative ideas (we will be
  discussing them in our upcoming featured
  article!).

7

• Operational biotech parks facilitating RD,
  production and industrial sector development are
  being setup by the Indian Government in Lucknow
  (Uttar Pradesh), Kochi (Kerala), Bangalore
  (Karnataka) and Guwahati (Assam). However, the
  2016-2017 Union Budget has left many in-house
  investors perturbed.

8
(No Transcript)
9

• It has been announced that the weighted tax
  deduction for RD expenses would be cut down from
  200 to 150 for upcoming financial years till
  2019-2020 after which it would be further limited
  to 100.

10

• This proposal has hindered various upcoming
  in-house investments slowing down Indias trial
  to becoming a global key player in biotech
  sector.

11

• For More Update, Visit Us

http//medgenera.com/